Actively Recruiting
Phase 2 Study of Ruxolitinib Treatment for Adults with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Led by William Shomali · Updated on 2025-12-23
10
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how well the drug ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders. This phase II clinical trial aims to determine the overall blood response rate to ruxolitinib and assess its safety. The study also looks at how many patients can reduce or stop corticosteroid use, the duration and time to response, progression-free survival, and overall survival. Participants receive ruxolitinib by mouth twice daily for 28 days per cycle. Treatment may continue for up to six cycles if the disease does not worsen and side effects remain manageable. The study focuses on patients with various eosinophilic conditions, including idiopathic hypereosinophilic syndrome, lymphocyte-variant hypereosinophilia, chronic eosinophilic leukemia, and JAK2-rearranged eosinophilic neoplasms. During the trial, participants undergo regular assessments including blood tests to monitor response and side effects. Researchers track outcomes such as overall response rate, adverse events, corticosteroid use changes, duration and time to response, and survival measures over three years. Participants must meet specific health criteria to join and will be closely monitored throughout the study period.
CONDITIONS
Brief Title
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Research Team
T
Tiffany Nguyen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
